Search Results

Containing any of the words

Only of the type

A Phase 3, Randomized, Active Comparator, Double-Blind, Multi-Center Study to Compare the Efficacy, Safety and Tolerability of ITCA 650 to Sitagliptin as Add-on Therapy to Metformin in Patients With Type 2 Diabetes Drug Clinical Trial

A Randomized, double-blind, placebo-controlled, multicenter phase III study of RAD001 Adjuvant Therapy in Poor Risk with Diffuse Large B-Cell Lymphoma (DLBCL) of RAD001 versus matching PlaceboAfter Patients Have Achieved Complete Response with First-line Rituximab Chemotherapy Drug Clinical Trial

A study of the factors predicting radiation exposure to contacts of Saudi patients treated with radioactive iodine (I 131): A preliminary study for patients’ criteria selection for possible high dose I131 therapy on out-patient basis in the future Drug Clinical Trial

A Phase 3, Randomized, Active Comparator, Double-Blind, Multi-Center Study to Compare the Efficacy, Safety and Tolerability of ITCA 650 to Sitagliptin as Add-on Therapy to Metformin in Patients With Type 2 Diabetes Drug Clinical Trial

A Randomized, double-blind, placebo-controlled, multicenter phase III study of RAD001 Adjuvant Therapy in Poor Risk with Diffuse Large B-Cell Lymphoma (DLBCL) of RAD001 versus matching PlaceboAfter Patients Have Achieved Complete Response with First-line Rituximab Chemotherapy Drug Clinical Trial

SFDA Detects 187 Violating Facilities During 1,959 Tours News

A Phase 2 Study for the Treatment of Anemia with Alpha (α)-Thalassemia to Determine the Efficacy and Safety of Luspatercept (BMS-986346/ACE-536) in Adults and Evaluate the Safety and Pharmacokinetics in Adolescents Drug Clinical Trial

A Phase 1/2, Global, Open-Label, Extension Study to Evaluate the Long-Term Safety and Clinical Activity of mRNA-3705 in Participants Previously Enrolled in Other Clinical Studies of mRNA-3705 Drug Clinical Trial

SFDA Monitors More than 500 violations in facilities that did not adhere to COVID-19 precautions during 2021 News

A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multinational Clinical Study to Evaluate the Efficacy and Safety of 2.0 mg/kg/Week and 2.0 mg/kg/Every Other Week BMN 110 in Patients With Mucopolysaccharidosis IVA (Morquio A Syndrome) Drug Clinical Trial